Efficacy and safety of iron-chelation therapy with deferoxamine, defer | DDDT
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond | Clinical Cancer Research
Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention | American Society of Nephrology
PDF) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
IJMS | Free Full-Text | Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism | HTML
PDF) Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. - Abstract - Europe PMC
Iron Chelation Therapy
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts: Molecular Therapy - Methods & Clinical Development
Frontiers | Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications | Neuroscience
Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention | American Society of Nephrology
Iron Overload in Chronic Anaemias Dick Wells MD
The Role of Deferiprone in Iron Chelation | NEJM
Renal clearable nanochelators for iron overload therapy | Nature Communications
Proposed mechanism of iron uptake by R. oryzae from... | Download Scientific Diagram
Iron overload and chelation therapy in myelodysplastic syndromes
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. - Abstract - Europe PMC
The role of iron and iron chelators in zygomycosis - Clinical Microbiology and Infection
Medicines | Free Full-Text | Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications | HTML
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity - ScienceDirect
View of THERAPEUTIC ADVANCEMENTS IN MANAGEMENT OF IRON OVERLOAD–A REVIEW | International Journal of Pharmacy and Pharmaceutical Sciences
Iron chelation therapy in transfusion-dependent thalassemia patients: | JBM
Deferoxamine (DFOA) uses, antidote effects, mechanism, indications and ADR's ☠ - YouTube
In vitro activity and mode of action of distamycin analogues against African trypanosomes - ScienceDirect
Deferoxamine Antidote: 2004
